🧠 This Week in Neuroscience: MS Gait Gains, ALS Survival, Migraine Advocacy, Brain Implants & More!
Get ready to dive into the latest breakthroughs transforming neuroscience! From EU policy pushes on migraine to cutting-edge implants helping paralyzed patients walk again, this week’s updates spotlight innovations reshaping how we understand and treat brain and nervous system disorders.
📌 What’s Inside This Week’s Update:
🌍 Migraine gains attention in the European Parliament’s health strategy
💉 Tiziana expands intranasal MS trial with Weill Cornell
🦵 PoNS Therapy shows long-term real-world gait benefits in MS
🧬 BrainStorm’s NurOwn extends survival in 90% of ALS patients
🧠 Cellectar’s glioma therapy shows disease control and 8.6-month OS in children
🧪 Polyrizon’s hydrogel achieves over 60% CNS-targeted nasal delivery
🧬 Capsida’s Parkinson’s gene therapy clears IND for Phase 1/2 launch
👁 GenSight’s LUMEVOQ early access fast-tracked for Q4 2025 in France
💊 Supernus acquires Sage and ZURZUVAE® in $795M CNS expansion
🧬 Paralyzed patients in Shanghai walk again after brain-spinal implant breakthrough
⚠️ Sarepta pauses ELEVIDYS use after fatal liver safety events in DMD patients
From migraine advocacy to neurorestorative implants, these updates are setting new standards in neuroscience innovation.
✅ Like, share, and subscribe for weekly updates on neuroscience, neurodegeneration, and clinical trials
#Neuroscience #BrainHealth #MigraineAwareness #MultipleSclerosis #ALS #Parkinsons #GeneTherapy #Neurotech #CNSResearch #LucidQuest #ClinicalTrials #Neurodegeneration #HealthcarePolicy #BiotechNews #NeuroInnovation #PatientAdvocacy #HealthcareConsulting